Aliskiren Fumarate

「心肌严重损害」最常隐匿于抗癌、抗感染与免疫治疗三大领域；牢记蒽环 - 曲妥珠单抗 - 免疫检查点抑制剂「三大红线」，一旦联用或序用，务必提前心脏监测、设定停药阈值，并让患者知晓胸闷气促即刻就诊。。 一、细胞毒类化疗药的拓展与机制深化 新增高危药物及特征 米托蒽醌：作为蒽环类衍生物，虽心脏毒性低于多柔比星，但累积剂量超过 110mg/m² 时，心衰发生率显著升高。其机制与铁离子介导的氧化应激相关，通过诱导心肌细胞线粒体渗透过渡孔开放，导致能量代谢衰竭。 5 - 氟尿嘧啶（5-FU）：心脏毒性发生率约 1.3%，有心脏病史者升至 4.6%，大剂量持续输注时可达 7.6%。主要表现为心绞痛、ST-T 改变、急性心梗，甚至心源性休克，机制与冠脉痉挛、内皮损伤及代谢产物氟柠檬酸抑制三羧酸循环有关。 紫杉醇类（紫杉醇、多西他赛）：常见窦性心动过缓、房室传导阻滞，严重时引发室性心动过速。机制涉及心肌细胞膜钙通道紊乱，且与低钾血症协同增加心律失常风险。 钾离子与化疗药心肌毒性的协同作用 蒽环类药物可通过抑制心肌细胞钠钾泵功能，导致细胞内钾离子外流异常，破坏静息电位稳定性，诱发室性早搏、QT 间期延长等心律失常。临床数据显示，接受蒽环类化疗的患者中，30% 会出现亚临床低钾（血钾 3.0-3.5mmol/L），此类患者心衰发生率较血钾正常者高 2.8 倍。此外，化疗期间的恶心呕吐、利尿剂辅助治疗等，会进一步加重低钾状态，形成 “药物直接损伤 + 电解质紊乱” 的双重打击。 防护策略优化 剂量管控：多柔比星累积剂量需严格控制在 450mg/m² 以下，女性或既往接受过纵隔放疗者，阈值降至 360mg/m²。 联合防护：右雷佐生需在蒽环类用药前 30 分钟输注，剂量按 1:10 比例匹配多柔比星，同时补充辅酶 Q10（100mg / 次，每日 3 次），减轻氧化应激对钾离子通道的损伤。 动态监测：化疗周期中每 3 天检测一次血钾，维持血钾浓度在 4.0-4.5mmol/L，轻度低钾者口服氯化钾缓释片，中重度低钾需静脉补钾（浓度≤0.3%，速度≤20mmol/h）。 二、靶向 / 小分子抑制剂的风险拓展 新增高危药物及机制 瑞戈非尼、阿帕替尼：作为 VEGFR 抑制剂，除导致血压升高外，可通过抑制肾小管钠钾交换，引发高钾血症（发生率约 8.3%）。高钾血症会使心肌静息电位绝对值减小，钠通道提前失活，导致传导阻滞甚至窦性停搏。 伊布替尼：布鲁顿酪氨酸激酶抑制剂，心脏毒性以房颤为主要表现（发生率 10-15%），机制与抑制心肌细胞钾离子外流通道（Kv1.3）有关，可加重 QT 间期延长，尤其在合并低钾时风险倍增。 维罗非尼、达拉非尼：BRAF 抑制剂，虽心脏毒性发生率较低（约 2%），但可诱发急性冠脉综合征，其机制与钾离子介导的冠脉平滑肌痉挛相关。 临床管理要点 用药前筛查：检测基线血钾、肾功能及心电图，合并慢性肾病者避免联用保钾利尿剂。 动态监测：用药期间每 2 周复查血钾，高钾血症者（血钾＞5.5mmol/L）需立即停用药物，静脉输注 10% 葡萄糖酸钙 10-20mL 对抗心肌毒性，同时给予胰岛素 + 葡萄糖促进钾离子内流。 协同干预：血压控制目标为＜130/80mmHg，优先选用 ACEI/ARB 类药物，既降压又可改善心肌重构，但需警惕其潜在的保钾作用。 三、免疫治疗相关心肌损害的细化管理 免疫检查点抑制剂（ICIs）的风险拓展 ICIs 相关心肌炎的发生率虽仅 0.06%-3.80%，但死亡率高达 39.7%-66.0%，其中 PD-1+CTLA-4 抑制剂联合治疗时死亡率升至 66%。除淋巴细胞性心肌炎外，还可并发心包炎、心律失常（以房室传导阻滞为主），且常与肌炎、重症肌无力等其他免疫相关不良事件并存。 钾离子在 ICIs 心肌炎中的作用 ICIs 可通过免疫介导的肾小管损伤，导致钾排泄障碍，同时炎症因子释放会影响心肌细胞钾离子通道表达，引发高钾血症。临床观察发现，ICIs 相关心肌炎患者中，42% 合并高钾血症（血钾＞5.0mmol/L），此类患者的救治成功率显著低于血钾正常者。 优化治疗方案 紧急处理：确诊后立即给予甲泼尼龙 1g/d 静脉冲击治疗，连续 3 天，同时检测血钾水平。高钾血症者需同步给予碳酸氢钠碱化血液，促进钾离子转移。 辅助治疗：在激素基础上，加用免疫球蛋白（2g/kg）改善心肌炎症，同时补充镁离子（硫酸镁 2g 静脉输注），通过激活钠钾泵促进钾离子内流，协同稳定心肌细胞膜。 停药指征：出现 Ⅲ 级及以上心肌炎（左室射血分数＜40%）需永久停用 ICIs，避免再次激发免疫反应。 四、抗微生物药的心肌毒性与钾离子调控 新增高危药物及机制 克林霉素：大环内酯类衍生物，可通过抑制肠道钾吸收及促进肾脏排钾，导致低钾血症（发生率约 5%）。长沙某医院曾报道一例患者因输注克林霉素 + 地塞米松，血钾降至 1.88mmol/L，心率达 240 次 / 分，诱发尖端扭转型室速。 头孢他啶、亚胺培南等广谱抗生素：长期使用可破坏肠道菌群平衡，减少钾离子吸收，同时通过影响肾小管功能增加钾排泄，尤其在老年患者中易引发低钾血症。 万古霉素：大剂量使用时可导致红人综合征，伴随心肌缺血，其机制与低钾介导的冠脉痉挛相关，严重时可诱发急性心梗。 临床用药规范 联合用药监测：避免大环内酯类 / 氟喹诺酮类与利尿剂、激素联用，确需联用者，用药前检测血钾，用药期间每 48 小时复查一次。 低钾预防：长期使用广谱抗生素者，预防性口服氯化钾（1g / 次，每日 2 次），同时补充维生素 B 族，改善肠道吸收功能。 急救处理：氟喹诺酮类诱发尖端扭转型室速时，除立即停药外，需静脉补钾至血钾 4.0-4.5mmol/L，同时给予硫酸镁 2g 静脉输注，必要时行电复律。 五、新增类别：影响电解质平衡的药物（以钾离子为核心） 利尿剂 排钾利尿剂：噻嗪类（氢氯噻嗪）、袢利尿剂（呋塞米）通过促进肾脏排钾，长期使用低钾发生率达 20-30%。低钾会使心肌自律性增高、传导性降低，诱发房性心动过速、室性早搏，严重时导致室颤。 保钾利尿剂：螺内酯、氨苯蝶啶可抑制钾排泄，与 ACEI/ARB 联用时，高钾血症发生率升至 15%。高钾血症早期表现为 T 波高尖，随血钾升高逐渐出现 QRS 波增宽、P 波消失，最终引发心脏停搏。 激素类药物 糖皮质激素（地塞米松、泼尼松）：通过促进肾小管钠钾交换，增加钾排泄，长期大剂量使用低钾发生率约 18%。如长沙市第三医院案例中，患者因口腔溃疡输注地塞米松 + 克林霉素，导致严重低钾血症诱发恶性心律失常。 盐皮质激素（氟氢可的松）：除保钠排钾外，可直接损伤心肌细胞，导致心肌纤维化，长期使用增加慢性心衰风险。 其他影响钾代谢的药物 洋地黄类药物：通过抑制钠钾 ATP 酶，导致细胞内低钾，增加心肌自律性，诱发室性心律失常。洋地黄中毒时，补钾是关键治疗措施，可纠正低钾状态并促进洋地黄排泄。 降压药：ACEI/ARB 类（依那普利、缬沙坦）、直接肾素抑制剂（阿利吉仑）可减少钾排泄，合并肾功能不全者需严格监测血钾。 六、钾离子异常与药物性心肌损害的协同机制 钾离子对心肌电生理的核心调控作用 心肌细胞的静息电位主要由钾离子平衡电位决定，正常血钾浓度（3.5-5.5mmol/L）是维持心肌兴奋性、自律性和传导性的基础。钾离子通过参与动作电位复极化过程，调节 QT 间期长度，其浓度异常会直接破坏心脏电活动稳定性。 低钾血症的致心肌损害机制 血钾＜3.5mmol/L 时，心肌细胞膜对钾的通透性下降，复极化 4 期钾离子外流减少，钠内流相对加速，导致自律性增高；同时静息电位绝对值增大，钠通道激活困难，传导速度减慢。这种电生理紊乱会诱发房性心动过速、室性早搏，严重低钾（＜2.5mmol/L）时可导致尖端扭转型室速，甚至心脏骤停。临床数据显示，药物相关性低钾血症患者中，12% 会出现严重心律失常，死亡率达 8.7%。 高钾血症的致心肌损害机制 血钾＞5.5mmol/L 时，心肌静息电位绝对值减小，接近阈电位水平，钠通道提前失活，0 期去极化速度和幅度下降，导致传导性显著降低；同时复极化 2 期钙离子内流受抑制，心肌收缩性减弱。血钾＞7.0mmol/L 时，可出现 P 波消失、QRS 波增宽，最终形成正弦波，转为心室颤动或心脏停搏。药物相关性高钾血症中，60% 与肾排钾障碍相关，尤其在联用保钾药物和肾功能不全患者中风险最高。 七、心肌保护与电解质紊乱纠正的精细化策略 基础防护原则 风险分层筛查：用药前评估患者年龄、基础心脏疾病、肾功能、电解质水平，对高危人群（如老年、慢性肾病、心衰病史）建立个体化监测方案。 避免高危联用：严禁蒽环类 + 曲妥珠单抗 + ICIs 三联使用；保钾利尿剂避免与 ACEI/ARB、肾素抑制剂联用；氟喹诺酮类避免与低钾血症相关药物（利尿剂、激素）联用。 患者教育：告知患者低钾血症常见症状（乏力、心悸、腹胀）和高钾血症表现（肢体麻木、心慌、呼吸困难），出现不适立即停药就诊。 电解质紊乱的精准纠正 低钾血症纠正 轻度低钾（3.0-3.5mmol/L）：口服氯化钾缓释片（1-2g / 次，每日 3 次），联合枸橼酸钾改善胃肠道耐受性，同时减少利尿剂剂量或更换为保钾型。 中度低钾（2.5-3.0mmol/L）：静脉补钾，浓度控制在 0.3% 以内，速度≤20mmol/h，每日补钾量不超过 80mmol。 重度低钾（＜2.5mmol/L）：心电监护下快速补钾（速度可达 40mmol/h），同时补充镁离子（硫酸镁 2-4g），因为低镁会影响钠钾泵功能，阻碍钾离子内流。 高钾血症急救 立即停用所有含钾药物和食物，建立静脉通路。 对抗心脏毒性：10% 葡萄糖酸钙 10-20mL 静脉推注（5-10 分钟），通过稳定心肌细胞膜减少钾离子影响。 促进钾转移：5% 碳酸氢钠 125-250mL 静脉滴注，或胰岛素 10U+50% 葡萄糖 50mL 静脉推注，促进钾离子从细胞外转入细胞内。 加速钾排泄：肾功能正常者给予呋塞米 20-40mg 静脉注射；肾衰竭患者需紧急血液透析，这是最有效的降钾措施。 针对性保护药物的优化使用 蒽环类化疗：右雷佐生需按 1:10 比例与蒽环类药物联用，同时口服 ACEI/β 受体阻滞剂（如贝那普利、美托洛尔），从用药第 1 周期开始持续使用 2 年，降低迟发性心衰风险。 靶向药物治疗：VEGFR 抑制剂相关高血压首选缬沙坦 + 氨氯地平联用，既降压又保护心肌，同时避免低钾或高钾血症。 抗生素治疗：长期使用广谱抗生素者，预防性补充氯化钾和益生菌，维持肠道钾吸收功能。 八、特殊人群的个体化管理 老年患者 老年患者肾功能生理性减退，钾排泄能力下降，同时常合并高血压、心衰等基础疾病，使用高危药物时电解质紊乱风险显著升高。建议： 用药剂量减至常规剂量的 70-80%，避免大剂量冲击治疗。 血钾监测频率增加至每 1-2 周一次，维持血钾在 3.8-4.5mmol/L。 优先选用肾排泄率低的药物，如多西他赛替代紫杉醇，减少肾脏负担。 肾功能不全患者 肾功能不全是药物相关性钾代谢紊乱的主要危险因素，肌酐清除率＜60mL/min 时，需： 避免使用保钾利尿剂、ACEI/ARB 类药物，确需使用时，初始剂量减半。 化疗药物（如顺铂、卡铂）需根据肾功能调整剂量，同时加强水化治疗，促进药物排泄。 定期检测血钾和肾功能，肌酐清除率＜30mL/min 者，建议每 3 天复查一次血钾。 合并基础心脏疾病患者 此类患者心肌储备功能下降，药物性心肌损害和电解质紊乱的耐受性更差。建议： 用药前完成心脏超声、心电图、心肌酶谱检查，评估心功能状态。 避免使用蒽环类、ICIs 等高危药物，确需使用时，提前给予右雷佐生、辅酶 Q10 等保护药物。 维持血钾在 4.0-4.5mmol/L，这一水平最有利于心肌电活动稳定，降低心律失常风险。 九、预后评估与长期随访 药物相关性心肌损害的预后与损伤程度、干预时机及电解质紊乱纠正情况密切相关。轻度损害（如无症状 QT 间期延长、轻度低钾）经停药和对症治疗后，多数可完全恢复；重度损害（如急性心衰、室颤、严重高钾血症）即使救治成功，也可能残留心肌纤维化，导致慢性心衰。 长期随访建议： 短期随访：停药后 1-3 个月内，每月复查心电图、血钾和心肌酶谱，评估心肌恢复情况。 长期监测：蒽环类药物治疗后，每年复查心脏超声，持续 5-10 年，早期发现迟发性心衰；ICIs 治疗后，随访 2 年，警惕免疫相关心肌损害的复发。 再用药指导：曾发生药物相关性心肌损害的患者，需避免再次使用同类药物，确需抗肿瘤治疗时，优先选用心脏毒性低的药物（如博来霉素、甲氨蝶呤），并提前制定心肌保护方案。 总结 药物相关性心肌损害的发生机制复杂，除药物直接损伤外，钾离子等电解质紊乱的协同作用是重要诱因。临床管理中，需建立 “风险筛查 - 动态监测 - 精准干预 - 长期随访” 的全流程体系：用药前评估电解质和心肾功能，用药期间强化血钾监测，出现异常时立即停药并针对性纠正电解质紊乱，同时结合药物类别选用合适的心肌保护剂。 尤其要重视蒽环类、曲妥珠单抗、ICIs “三大红线” 药物，避免高危联用；对于影响钾代谢的药物（如利尿剂、激素、抗生素），需严格把控剂量和疗程，确保血钾维持在 3.8-4.5mmol/L 的安全范围。通过多学科协作（肿瘤科、心血管科、药剂科），实现药物疗效与心脏安全的平衡，最大程度降低心肌严重损害的发生风险。

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli™, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension COMMACK, NY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Compared to Third Quarter 2024: Launched sales of Arbli™ (losartan potassium).Net revenue increased from approximately $65 thousand to $590 thousand.Gross profit increased from approximately $4 thousand to $575 thousand. “Q3 was a transformational quarter for Scienture as we commenced sales of Arbli™,” commented Narasimhan Mani, President and Co-CEO of Scienture. “We delivered strong results this quarter, with significant increases in net revenues and gross profit as we entered full commercial scale-up of our first FDA-approved product, Arbli™. In the past month, Arbli™ was added to key national payor formularies, expanding access to over 100 million covered lives, and we secured GPO agreements reaching more than 2,500 healthcare institutions, representing potential penetration into roughly 20% of the U.S. institutional market. As we broaden our marketing efforts and demand builds across retail, institutional, and long-term care channels, we see significant potential for sustained adoption and long-term value creation. Subsequent to the end of the third quarter, we fundamentally strengthened our balance sheet by substantially reducing our outstanding debt and significantly enhancing our cash position to over $8 million as of November 13, 2025. Having optimized our capital structure, we are now strongly positioned and adequately capitalized to advance our commercial and operational priorities.” “Backed by a strong commercial infrastructure and the successful launch of Arbli™, Scienture is preparing to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment, in Q1 2026,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “REZENOPY® is the most potent naloxone HCl product currently available, leveraging a proven active ingredient and delivery method while offering increased effectiveness against today’s more powerful opioids. Additionally, our development pipeline remains strong, and we continue to evaluate additional opportunities to add accretive products to our commercial portfolio. Delivering sustained shareholder value remains the Company’s core priority.” About Arbli™ Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook. Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature. INDICATION Arbli™ is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. IMPORTANT SAFETY INFORMATION Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).Do not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in patients with severe hepatic impairment.The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917. Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider. About Hypertension Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg. About Scienture Holdings, Inc. SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com. Cautionary Statements Regarding Forward-Looking Statements This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, our strategies related to those products, and our future financial condition and results from operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law. Contact: SCIENTURE HOLDINGS, INC.20 Austin BlvdCommack, NY 11725Phone: (866) 468-6535Email: IR@Scienture.com (Tables follow) Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.Condensed Consolidated Balance SheetsAs of September 30, 2025 and December 31, 2024(Unaudited) September 30, December 31, 2025 2024 ASSETS Current assets: Cash $355,692 $308,096 Accounts receivable, net 590,050 11,106 Inventory 234,521 - Prepaid expenses 240,811 4,560 Notes receivable - related party - 1,300,000 Other receivables - 4,138,770 Deferred offering costs - 534,800 Current assets of discontinued operations - 8,145 Total current assets 1,421,074 6,305,477 Property, plant and equipment, net 16,000 17,500 Deposits - 22,039 Notes receivable 5,000,000 - Interest receivable 62,500 - Intangible assets, net 76,400,000 76,400,000 Goodwill 21,372,960 21,372,960 Operating lease right-of-use assets 23,360 201,433 Deferred tax asset 534,396 534,396 Total assets $104,830,290 $104,853,805 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $3,672,860 $2,898,683 Accrued liabilities 984,825 1,313,731 Other current liabilities - 5,441 Loan payable, related party 531,000 415,000 Convertible note, net of debt discount - current portion 2,000,000 2,285,423 Operating lease liability - current 24,137 63,334 Warrant liability 138,624 919,935 Current liabilities of discontinued operations - 5,346 Total current liabilities 7,351,446 7,906,893 Convertible notes, net of debt discount - 612,275 Derivative liability - 2,296,834 Operating lease liability - net of current portion - 156,469 Development agreement liability 1,285,000 1,285,000 Deferred tax liability 13,524,213 13,524,213 Total liabilities 22,160,659 25,781,684 Commitments and contingencies (Note 15) Stockholders’ equity (deficit): Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of both September 30, 2025 and December 31, 2024 - - Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both September 30, 2025 and December 31, 2024 - - Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and outstanding as of both September 30, 2025 and December 31, 2024 - - Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and outstanding as of both September 30, 2025 and December 31, 2024 - - Common stock, $0.00001 par value; 100,000,000 shares authorized; 23,132,260 and 8,750,582 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 231 87 Additional paid-in capital 135,100,304 118,111,007 Accumulated deficit (52,430,904) (39,038,973)Total stockholders’ equity 82,669,631 79,072,121 Total liabilities and stockholders’ equity $104,830,290 $104,853,805 Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.Condensed Consolidated Statements Of OperationsFor the Three and Nine Months Ended September 30, 2025 and 2024(Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Revenues $590,050 $64,861 $600,308 $83,560 Cost of goods sold 15,429 60,978 25,014 80,380 Gross profit 574,621 3,883 575,294 3,180 Operating expenses: Wage and salary expense 251,747 708,977 1,721,554 1,243,621 Professional fees 1,320,845 593,364 1,943,458 1,282,053 Accounting and legal expense 1,018,737 619,227 1,871,245 1,129,982 Technology expense 9,756 157,474 92,784 295,763 General and administrative 2,165,398 168,649 6,449,110 5,284,231 Research and development 169,344 1,253,983 1,587,572 1,253,983 Total operating expenses 4,935,827 3,501,674 13,665,723 10,489,633 Operating loss (4,361,206) (3,497,791) (13,090,429) (10,486,453) Non-operating income (expense): Change in fair value of warrant liability 59,203 502,178 781,311 (392,843)Change in fair value of derivative liability 2,356,428 - 2,296,834 - Loss on conversion of note payable 43,200 - (53,446) - Loss on disposition of subsidiaries 97,324 - (288,204) - Interest income 1,120 29,445 89,710 133,397 Loss on disposal of asset - - - (374,968)Interest expense (1,803,430) (217,433) (3,127,707) (320,897)Total non-operating expense 753,845 314,190 (301,502) (955,311) Net loss from continuing operations (3,607,361) (3,183,601) (13,391,931) (11,441,764)Benefit / (provision) for income taxes - - - - Net loss from continuing operations, net of tax (3,607,361) (3,183,601) (13,391,931) (11,441,764)Net income from discontinued operations, net of tax - - - 27,670,294 Net (loss) income $(3,607,361) $(3,183,601) $(13,391,931) $16,228,530 Net loss per common share from continuing operations Basic $(0.19) $(1.34) $(0.94) $(7.10)Diluted $(0.19) $(1.34) $(0.94) $(7.10)Net (loss) income per common share from discontinued operations Basic $- $- $- $17.17 Diluted $- $- $- $14.64 Net (loss) income per common share Basic $(0.19) $(1.34) $(0.94) $10.07 Diluted $(0.19) $(1.34) $(0.94) $8.59 Weighted average common shares outstanding Basic 18,957,653 2,373,848 14,269,905 1,611,221 Diluted 18,957,653 2,373,848 14,269,905 1,889,504